89407-43-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-ethoxybenzoic acid is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be chemically modified and incorporated into the structure of new drug molecules. Its presence in the molecular structure can contribute to the drug's efficacy, stability, and other desired properties.
Used in Organic Synthesis:
In the field of organic chemistry, 4-Bromo-2-ethoxybenzoic acid is used as a building block for the creation of other organic compounds. Its bromine atom and ethoxy group make it a versatile component that can be further reacted to form a wide range of chemical products.
Used in Research and Development:
4-Bromo-2-ethoxybenzoic acid is utilized in research and development settings to explore its potential applications and to study its chemical properties. Scientists and researchers use 4-Bromo-2-ethoxybenzoic acid to investigate new methods of synthesis, drug discovery, and the development of novel materials.
It is important to handle 4-Bromo-2-ethoxybenzoic acid with care, as it can be harmful if ingested or inhaled. Proper safety measures should be taken during its synthesis, use, and disposal to minimize any potential risks.

Upstream product

• 939983-36-5 ethyl 4-bromo-2-ethoxybenzoate 
• 1666-28-0 4-bromosalicylic acid 

Downstream Products

• 855482-06-3 4-bromo-2-ethoxy-N-(methylsulfonyl)benzamide 
• 1352719-52-8 2-(4-bromo-2-ethoxyphenyl)acetonitrile 
• 1094750-85-2 (4-bromo-2-ethoxyphenyl)methanol 

Relevant academic research and scientific papers

Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1

Bone Morphogenetic Protein 1 (BMP1) inhibition is a potential method for treating fibrosis because BMP1, a member of the zinc metalloprotease family, is required to convert pro-collagen to collagen. A novel class of reverse hydroxamate BMP1 inhibitors was

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: (I) wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP1, TLL1 AND/OR TLL2 INHIBITORS

Compounds of Formulas (I) and (II) and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and(iv) CH 2 OH;R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH,-NH 2, -C(=O)NH 2, and -CH 2 OH; R 4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1;R 11a, R 11b, R 11c and R 11d are independently selected from H, halo, C1-4 alkyl, C 1-4 fluoroalkyl, C 3-4 cycloalkyl, C 1-4 alkyloxy, NH-C 1-4 alkyl and cyano; R 12a and R 12b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH 2 OH; R 12c and R 12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH;R 12e is H or Me; R 13a and R 13b are independently selected from H and Me; R 14 is either H or Me; R 16a and R 16b are independently selected from H and Me; R 6 is selected from H, OMe, and OEt.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.